“…The total sample size was 2177 participants. The studies were conducted in Iran (Karandish et al, 2021; Karandish et al, 2022; Yari et al, 2021), Japan (Funamoto et al, 2019), Italy (Cicero et al, 2020; Colletta et al, 2020; Derosa, D'angelo, et al, 2020; Derosa, Maffioli, et al, 2020), China (Ming et al, 2021; Shanobin et al, 2007; Wang et al, 2020; Yang et al, 2017, 2021; Yang, Ling, et al, 2020; Yang, Liu, et al, 2020; Ye et al, 2015, 2021; Zhang et al, 2018), USA (Moreno‐Ulloa et al, 2018; Pollack et al, 2017), Brazil (Ribeiro et al, 2019), and Australia (Thota et al, 2019; Thota et al, 2020). The participants were prediabetic patients (or defined as patients with IGT, IFG, IGR, or hyperglycemia without overt diabetes).…”